It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Exertional heat illness (EHI) and malignant hyperthermia (MH) are life threatening conditions associated with muscle breakdown in the setting of triggering factors including volatile anesthetics, exercise, and high environmental temperature. To identify new genetic variants that predispose to EHI and/or MH, we performed genomic sequencing on a cohort with EHI/MH and/or abnormal caffeine-halothane contracture test. In five individuals, we identified rare, pathogenic heterozygous variants in ASPH, a gene encoding junctin, a regulator of excitation-contraction coupling. We validated the pathogenicity of these variants using orthogonal pre-clinical models, CRISPR-edited C2C12 myotubes and transgenic zebrafish. In total, we demonstrate that ASPH variants represent a new cause of EHI and MH susceptibility.
The genetic cause(s) of malignant hyperthermia and exertional heat illness are unknown in approximately 30% of cases. To address this barrier, the authors performed genome sequencing on a large cohort of cases, identifying rare variants in ASPH, a gene encoding junctin, and validating them in animal and cell models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Hospital for Sick Children, Program for Genetics and Genome Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
2 University of Rochester, Department of Physiology, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174)
3 Hospital for Sick Children, Centre for Computation Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
4 Malignant Hyperthermia Unit, Department of Anesthesia, Toronto General Hospital, Toronto, Canada (GRID:grid.417184.f) (ISNI:0000 0001 0661 1177)
5 Baylor College of Medicine, Department of Molecular Physiology and Biophysics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
6 University of Leeds, Leeds Institute of Medical Research at St. James’s, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403)
7 University of Leeds, Leeds Institute of Medical Research at St. James’s, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403); Malignant Hyperthermia Unit, St. James’s University Hospital, Leeds, UK (GRID:grid.443984.6) (ISNI:0000 0000 8813 7132)
8 Hospital for Sick Children, Program for Genetics and Genome Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); Hospital for Sick Children, Division of Neurology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Paediatrics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)